Aug. 6 at 2:03 PM
$ACRS OMG. It is going to he a monster 3rd and 4th Quarter. This truly has a shot of
$15 and if anything such as merger/buyout/short squeeze, it definitely can explode to
$25+
Reports Q2 revenue
$1.6M, consensus
$1.38M. As of June 30, Aclaris had cash, cash equivalents and marketable securities of
$170.6M vs.
$151.4M as of December 31, 2025. CEO Neal Walker. “We expect to provide three clinical data readouts, including placebo-controlled top line results from our two Phase 1b POC trials of our anti-TSLP/IL-4Ralpha bispecific antibody ATI-052 in both asthma and atopic dermatitis and the Phase 2 AD trial of our anti-TSLP monoclonal antibody bosakitug. Other key catalysts include initiation of a Phase 2b clinical program with ATI-052 and a Phase 2b trial in lichen planus with modzatinib. Finally, our data presented recently at the FASEB conference support the best-in-class potential of our investigational ITK inhibitor ATI-9494, for which we expect to file an IND late this year.”
